Biocon subsidiary Biocon Biologics has received approval from the Drugs Controller General of India (DCGI) for the use of extracorporeal blood purification (EBP) device CytoSorb in the treatment of COVID-19 patients. The license will be effective until control of the COVID-19 outbreak in the country.
What this means:
With the regulatory nod, Biocon Biologics will be able to treat COVID-19 patients, aged 18 and above, who have been admitted to the intensive care units (ICU) with confirmed or imminent respiratory failure. CytoSorb is an in-licensed unique device that reduces cytokine storm in critically ill patients and was introduced by Biocon in India in 2013. The approval will provide an impetus to the Company in their role in aiding Corona Virus Treatment efforts.
